Inhibition of cyclin-dependent kinases - A review of the recent patent literature

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 3, 2006, Pages 357-367

  Basso, Andrea D ^a   Doll, Ronald J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anticancer agents; Apoptosis; BMS 387032; Cdk1; Cdk2; Cdk4; Cell cycle; Cyclin dependent kinases; Flavopridol; Roscovitine; Tumorigenesis; UCN 01

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE;

ANIMAL; APOPTOSIS; CELL CYCLE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; NEOPLASM; PATENT; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASES; HUMANS; NEOPLASMS; PATENTS AS TOPIC;

EID: 39049156915     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206778776916     Document Type: Review

References (100)

1. Fry DW, Garrett MD. Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer. Curr Opin Oncol Endocr Metab Invest Drugs 2000; 2(1): 40-59.
2. Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J. Clinical anticancer drug development: targeting the cyclindependent kinases. Br J Cancer 2005; 92(1): 7-12.
3. Serizawa H, Makela TP, Conaway JW, Conaway RC, Weinberg RA, Young RA. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature 1995; 374(6519): 280-82.
4. Shiekhattar R, Mermelstein F, Fisher RP, et al. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature 1995; 374(6519): 283-87.
5. Leclerc V, Tassan JP, O'Farrell PH, Nigg EA, Leopold P. Drosophila Cdk8, a kinase partner of cyclin C that interacts with the large subunit of RNA polymerase II. Mol Biol Cell 1996; 7(4): 505-13.
6. Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E. Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 1996; 12(12): 2631-40.
7. Rickert P, Corden JL, Lees E. Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene 1999; 18(4): 1093-102.
8. Garriga J, Jayaraman AL, Limon A, et al. A dynamic equilibrium between CDKs and PP2A modulates phosphorylation of pRB, p107 and p130. Cell Cycle 2004; 3(10): 1320-30.
9. Ren S, Rollins BJ. Cyclin C/Cdk3 promotes Rb-dependent G0 exit. Cell 2004; 117(2): 239-51.
10. Maccioni RB, Otth C, Concha, II, Munoz JP. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem 2001; 268(6): 1518-27.
11. Hu B, Mitra J, van den Heuvel S, Enders GH. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominantnegative mutant in human cells. Mol Cell Biol 2001; 21(8): 2755-66.
12. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 262(5142): 2050-54.
13. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15(5): 2612-24.
14. Tsai LH, Lees E, Faha B, Harlow E, Riabowol K. The Cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 1993; 8(6): 1593-602.
15. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. Embo J 1992; 11(3): 961-71.
16. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3(3): 233-45.
17. Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35(1): 25-31.
18. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13(20): 1775-85.
19. Rane SG, Dubus P, Mettus RV, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999; 22(1): 44-52.
20. Tsutsui T, Hesabi B, Moons DS, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999; 19(10): 7011-19.
21. Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118(4): 493-504.
22. Parisi T, Beck AR, Rougier N, et al. Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. Embo J 2003; 22(18): 4794-803.
23. Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell 2003; 114(4): 431-43.
24. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995; 9(19): 2364-72.
25. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995; 82(4): 621-30.
26. Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18(4): 747-55.
27. Mihara M, Shintani S, Nakashiro K, Hamakawa H. Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Oral Oncol 2003; 39(1): 49-55.
28. Lane ME, Yu B, Rice A, Lipson KE, Liang C, Sun L, et al. A novel Cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001; 61(16): 6170-77.
29. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999; 96(8): 4325-29.
30. Abal M, Bras-Goncalves R, Judde JG, et al. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 2004; 23(9): 1737-44.
31. Fukuoka K, Adachi J, Nishio K, et al. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn J Cancer Res 1997; 88(10): 1009-16.
32. Konishi Y, Lehtinen M, Donovan N, Bonni A. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell 2002; 9(5): 1005-16.
33. Meikrantz W, Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 1996; 271(17): 10205-09.
34. Rideout HJ, Wang Q, Park DS, Stefanis L. Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J Neurosci 2003; 23(4): 1237-45.
35. Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996; 56(14): 3199-202.
36. Hsu SL, Yin SC, Liu MC, Reichert U, Ho WL. Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. Exp Cell Res 1999; 252(2): 332-41.
37. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994; 201(2): 589-95.
38. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclindependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56(13): 2973-78.
39. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996; 56(21): 4856-61.
40. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992; 84(22): 1736-40.
41. Drees M, Dengler WA, Roth T, et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 1997; 3(2): 273-79.
42. Patel V, Senderowicz AM, Pinto D. Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998; 102(9): 1674-81.
43. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16(9): 2986-99.
44. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002; 20(19): 4074-82.
45. Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000; 18(2): 371-75.
46. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19(7): 1985-92.
47. Burdette-Radoux S, Tozer RG, Lohmann RC, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004; 22(3): 315-22.
48. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21(9): 1740-45.
49. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, Cdk2 and Cdk5. Eur J Biochem 1997; 243(1-2): 527-36.
50. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002; 102(5): 463-68.
51. Mgbonyebi OP, Russo J, Russo IH. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 1999; 59(8): 1903-10.
52. Misra RN, Xiao HY, Kim KS, et al. N-(cycloalkylamino)-acyl-2-aminothiazole inhibitors of cyclin dependent kinase 2. J Med Chem 2004; 47(7): 1719-28.
53. Takahashi I, Asano K, Kawamoto I, Tamaoki T, Nakano H. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation. J Antibiot (Tokyo) 1989; 42(4): 564-70.
54. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclindependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1996; 219(3): 778-83.
55. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002; 21(11): 1727-38.
56. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60(8): 2108-12.
57. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991; 51(18): 4888-92.
58. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993; 53(9): 2081-86.
59. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19(8): 2319-33.
60. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005; 23(9): 1875-84.
61. Lara PN Jr, Mack PC, Synold T, et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 2005; 11(12): 4444-50.
62. Siemeister G, Briem H, Brumby T, et al. ZK-304709, the oral multitarget tumor growth inhibitor, acts via inhibition of cell cycle progression and tumor-induced angiogenesis. Proceedings of the American Association of Cancer Research 2005 Meeting; abstract 5842.
63. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular Cancer Therapeutics 2004; 3 (11): 1427-37.
64. Fiswcher PM, Lane DP. Inhibitors of cyclin-dependent kinases as anticancer therapeutics. Curr Med Chem 2000; 7: 1213-45.
65. Kimball SD, Webster KR. In: Annual Reports in Medicinal Chem-36, Cell cycle kinases and checkpoint regulation in cancer, Philadelphia, Academic Press. 2001; 139-48.
66. Lal, B., Joshi, K.S., Kulkarni, S.A., Mascarenhas, M., Kamble, S.G., Rathos, M.J., Joshi R.D.: WO04004632A2, WO04004632A3 (2004) and WO04004632C1 (2005).
67. Fischer, P., Jarman, M., McDonald, E., Nutley, B., Raynaud, F., Wilson, S., Workman, P.: WO04016612A2 and WO04016612A3 (2004).
68. Fischer, P., Jarman, M., McDonald, E. Nutley, B., Raynaud, F., Wilson, S., Workman, P.: WO04016613A2 and WO04016613A3 (2004).
69. Paruch, K., Guzi, T.J., Dwyer, M.P., Doll, R.J., Girijavallabhan, V.M.: WO04026310A1 (2004) and WO04026310C1 (2005).
70. Paruch, K., Guzi, T.J., Dwyer, M.P., Doll, R.J., Girijavallabhan, V.M., Mallams.K.: WO04026877A1 (2004).
71. Dwyer, M.P., Guzi, T.J., Paruch, K., Doll, R.J., Keertikar, K.M., Girijavallabhan, V.M.: WO04026867A2 and WO04026867A3 (2004).
72. Guzi, T.J., Paruch, K., Dwyer, M.P., Doll, R.J., Girijavallabhan, V.M., Dillard, L.W., Tran, V.D., He, Z.M., James, R.A., Park, H.: WO04022559A1 (2004).
73. Guzi, T.J., Paruch, K., Dwyer, M.P. Doll, R.J., Girijavallabhan, V.M., Dillard, L.W., Tran, V.D., He, Z.M., James, R.A., Park, H.: WO04022560A1 (2004) and WO04022560C2 (2005).
74. Guzi, T.J., Paruch, K., Dwyer, M.P. Doll, R.J., Girijavallabhan, V.M., Mallams, A., Alvarez, C.S., Keertikar, K.M., Rivera, J., Chan, T.-Y., Madison, V., Fischmann, T.O., Dillard, L.W., Tran, V.D., He, Z.M., James, R.A., Park, H., Paradkar, V.M., Hobbs, D.W.: WO04022561A1 (2004).
75. Guzi, T.J., Paruch, K., Dwyer, M.P., Doll, R.J., Girijavallabhan, V.M., Alvarez, C.S., Chan, T.-Y., Knutson, C., Madison, V., Fischmann, T.O., Dillard, L.W., Tran, V.D., He, Z.M., James, R. A., Park, H.: WO04026229A2 and WO04026229A3 (2004).
76. Dwyer, M.P., Guzi, T.J., Paruch, K., Doll, R.J., Keertikar, K.M., Girijavallabhan, V.M.: WO04026872 (2004).
77. Harris, P.A., Jung, D.K., Peel, M.R., Reno, M.J., Rheault, T.R., Stanford, J.B., Stevens, K.L., Veal, J.M.: WO03051886A1 (2003) and WO03051886C1 (2004).
78. Markwalder, J.A., Seitz, S.P., Sherk, S.R.: WO03063764A3 (2003).
79. Damour, D., Carry, J.-C., Nemecek, P., Terrier, C., Nardi, F., Filoche, B., Cherrier, M.-P., Bezard, D.: WO03078402A1 (2003).
80. Ledford, B.E.: WO03101989A1 (2003).
81. Berdini, V., Padova, A., Saxty, G., Woolford, A.J.-A., Wyatt, P.G.: WO04014864A1 (2004).
82. Berdini, V., Carr, M., Saxty, G., Woolford, A.J.-A., Wyatt, P.G.: WO04014922A1 (2004).
83. Garcia-Echeverria, C., Capraro, H.-G., Furet, P.: WO03097641A2 and WO03097641A3 (2003).
84. Repine, J.T.: WO03062246A1 (2003).
85. Lucking, U., Kruger, M., Jautelat, R., Prein, O., Siemeister, G., Ernst, A.: WO03076437A1 (2003).
86. Kuo, G.-H., Deangelis, A., Wang, A., Zhang, Y., Emanuel, S.L., Middleton, S.A.: WO04009562A1 (2004).
87. Lucking, U., Siemeister, G.: WO04026881A1 (2004).
88. Woolford, A.J.-A., Berdini, V., Oreilly, M., Padova, A., Saxty, G., Wyatt, P.G.: WO04004730A2 and WO04004730A3 (2004).
89. Li X, Huang P, Cui JJ, Zhang J, Tang C. Novel pyrrolyllactone and pyrrolyllactame indolinones as potent cyclic-dependent kinase 2 inhibitors. Bioorg Med Chem Lett 2003; 13: 1939-1942.
90. Kley, J., Heckel, A., Hilberg, F., Roth, G.J., Lehmann-Lintz, T., Lotz, R.R.H., Tontsch-Grunt, U., Van, M.J.C.A.: WO04026829A2 and WO04026829A3 (2004).
91. Dermatakis A, Luk KC, DePinto W. Synthesis of Potent Oxindole CDK2 Inhibitors. Bioorganic and Med Chem 2003; 11: 1873-81.
92. Luk KC, Simcox ME, Schutt A, et al. A new series of potent oxindole inhibitors of CDK2. Bioorganic and Med Chem Lett 2004; 14: 913-17.
93. Haydar, S.N.: WO03078647A2 and WO03078647A3 (2003).
94. Lacrampe, J.F.A., Connors, R.W., Ho, C.Y., Richardson, A., Freyne, E.J.E., Buijnsters, P. J. J., Bakker, A.C.: WO04007498A2, WO04007498A3 and WO04007498C2 (2004).
95. Lacrampe, J.F.A., Connors, R.W., Ho, C.Y., Richardson, A., Freyne, E.J.E., Buijnsters, P.J.J., Bakker, A.C.: WO04007499A1 (2004).
96. Cannolly, C.J., Deur, C.J., Hamby, D.W., Hoyer, D.W.; Limberakis, C., Reed, J.E., Schroeder, M.C., Taylor, C.B.: WO04011465A1 (2004).
97. Byth KF, Cooper C, Culshaw JD, et al. Imidazole[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Bioorganic and Med Chem Lett 2004; 14: 2249-52
98. Markwalder JA, Arnone MR, Benfield PA, et al. Synthesis and biological evaluation of 1-Aryl-45-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases. J Med Chem 2004; 47: 5894-11.
99. VanderWel SN, Harvey PL, McNamara DJ, et al. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclic-dependent kinase 4. J Med Chem. 2005; 48: 2371-87.
100. Lin R, Connolly PJ, Huang S, et al. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent cyclic-dependent kinase inhibitors: Synthesis and evaluation of biological activities. J Med Chem 2005; 48: 4208-11.